PT - JOURNAL ARTICLE AU - Strebel, Sven AU - Baust, Katja AU - Grabow, Desiree AU - Byrne, Julianne AU - Langer, Thorsten AU - Zehnhoff-Dinnesen, Antoinette am AU - Kuonen, Rahel AU - Weiss, Annette AU - Kepak, Tomas AU - Kruseova, Jarmila AU - Berger, Claire AU - Calaminus, Gabriele AU - Sommer, Grit AU - Kuehni, Claudia E. AU - the PanCareLIFE Consortium TI - Auditory Complications among Childhood Cancer Survivors and Health-related Quality of Life: A PanCareLIFE study AID - 10.1101/2023.03.30.23286995 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.30.23286995 4099 - http://medrxiv.org/content/early/2023/03/31/2023.03.30.23286995.short 4100 - http://medrxiv.org/content/early/2023/03/31/2023.03.30.23286995.full AB - Auditory complications are potential side effects from childhood cancer treatment. Yet, limited evidence exists about the impact of auditory complications—particularly tinnitus—on health-related quality of life (HRQoL) among childhood cancer survivors (CCS). We determined the prevalence of hearing loss and tinnitus in the large European PanCareLIFE cohort of CCS and examined its effect on HRQoL. We included CCS from four European countries who were diagnosed at age ≤ 18 years; survived ≥ 5 years; and aged 25–44 years at study. We assessed HRQoL (Short Form 36), hearing loss, and tinnitus using questionnaires. We used multivariable linear regression to examine associations between these two auditory complications and HRQoL adjusting for socio-demographic and clinical factors. Our study population consisted of 6,318 CCS (53% female; median age at cancer diagnosis 9 years interquartile range [IQR] 5–13 years) with median age at survey of 31 years (IQR 28–35 years). Prevalence was 7.5% (confidence interval [CI]: 6.9–8.2) for hearing loss and 7.6% (CI: 6.4–9.0) for tinnitus. CCS with hearing loss had impaired physical (coefficient [coef.] - 4.3, CI: -7.0 to -1.6) and mental (coef. -3.2, CI: -5.5 to -0.8) HRQoL when compared with CCS with normal hearing. Tinnitus was also associated with impaired physical (coef. -8.2, CI: -11.8 to -4.7) and mental (coef. -5.9, CI: -8.8 to -3.1) HRQoL. We observed the lowest HRQoL among CCS with both hearing loss and tinnitus. Our findings indicate timely treatment of hearing loss and tinnitus may contribute to quality of life of survivors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPanCareLIFE (Grant no. 602030) is a collaborative project in the 7th Framework Program of the European Union. The EU Commission takes no responsibility for any use made of the information set out.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:PanCareLIFE is a multinational collaborative research project that has harmonized and combined data from regional and national cohorts across Europe. Data collection and analysis for each cohort was approved by the responsible ethics committee in each participating country. For Germany this is the Ethics Committee of the Medical Association of Westphalia-Lippe and the Medical faculty of the Westphalian Wilhelms University (2012-530-f-S), for Switzerland the Cantonal Ethics Committee of the Canton of Bern (KEK-BE: 166/2014; 2021-01462), for the Czech Republic the Ethics Committee for Multi-Centric Clinical Trials of the University Hospital Motol (EK-1723/13) and the Multi-Centric Ethics Committee of the University Hospital Brno (approval date: 2014/10/22), and for France the Personal Protection Committee South East 1 (CPP: 2015-23).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the information of this manuscript were accessed on secured servers of the Institute of Social and Preventive Medicine at the University of Bern. Individual-level sensitive data can only be made available for researchers who fulfil the respective legal requirements. All data requests should be communicated to the corresponding author.BMIBody Mass IndexBPBodily painCCSChildhood cancer survivorsCCSSAmerican Childhood Cancer Survivor StudyCHSwitzerlandCI 95%Confidence intervalCNSCentral nervous systemCoef.Estimated beta coefficient from linear regressionCRTCranial radiation therapyCZThe Czech RepublicDEGermanyFRFranceGHGeneral healthHRQoLHealth-related quality of lifeHSCThematopoietic stem cell transplantationICCC-3International Classification of Childhood Cancer, Third editionIQRInterquartile rangeMCSMental component summaryMHMental healthPCLPanCareLIFEPCSPhysical component summaryPFPhysical functioningRERole emotionalRPRole physicalSCCSSSwiss Childhood Cancer Survivor StudySFSocial functioningSF-36Short-Form 36 questionnaireVTVitality